<div id="page0" style="width:595.3pt;height:793.7pt">
<p style="top:53.2pt;left:115.2pt;line-height:25.2pt"><b><i><span style="font-family:Times New Roman,serif;font-size:25.2pt;color:#2a4627">nutrients</span></i></b></p>
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<img style="position:absolute;transform:matrix(.15624357,0,-0,.1565575,485.88453,-25.217606)" src="data:image/png;base64,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">
<p style="top:100.5pt;left:76.2pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Review</span></i></p>
<p style="top:113.4pt;left:76.5pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">Inositol and Non-Alcoholic Fatty Liver Disease:</span></b></p>
<p style="top:133.6pt;left:75.8pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">A Systematic Review on De&#xfb01;ciencies</span></b></p>
<p style="top:153.9pt;left:76.5pt;line-height:17.9pt"><b><span style="font-family:URWPalladioL,serif;font-size:17.9pt">and Supplementation</span></b></p>
<p style="top:190.0pt;left:76.1pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Arianna Pani</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,2,</span></b></sup><sup><span style="font-family:Pxbsy,serif;font-size:7.6pt">&#x2020;</span></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Riccardo Giossi</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,2,</span></b></sup><sup><span style="font-family:Pxbsy,serif;font-size:7.6pt">&#x2020;</span></sup></p>
<p style="top:190.0pt;left:262.1pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Danilo Menichelli</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">3,</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">*</span></b></p>
<p style="top:190.0pt;left:373.6pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Veronica Andrea Fittipaldo</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">4</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span></b></p>
<p style="top:203.5pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Francesca Agnelli</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">5</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Elvira Inglese</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">6</span></b></sup></p>
<p style="top:203.5pt;left:247.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Alessandra Romandini</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Rossana Roncato</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,7</span></b></sup></p>
<p style="top:203.5pt;left:468.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span></b></p>
<p style="top:217.0pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Basilio Pintaudi</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">8</span></b></sup><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">, Francesco Del Sole</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">3</span></b></sup></p>
<p style="top:217.0pt;left:265.7pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and Francesco Scaglione</span></b><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt"> </span></b><sup><b><span style="font-family:URWPalladioL,serif;font-size:7.6pt">1,6</span></b></sup></p>
<p style="top:234.2pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">1</span></p>
<p style="top:235.9pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Department of Oncology and Hemato-oncology, Postgraduate School of Clinical Pharmacology,</span></p>
<p style="top:248.0pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">University of Milan, 20129 Milan, Italy; arianna.pani@unimi.it (A.P.); riccardo.giossi@unimi.it (R.G.);</span></p>
<p style="top:260.1pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">alessandra.romandini@unimi.it (A.R.); rroncato@cro.it (R.R.); francesco.scaglione@unimi.it (F.S.)</span></p>
<p style="top:270.5pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">2</span></p>
<p style="top:272.2pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Department of Neuroimmunology and Neuromuscular Diseases, Fondazione I.R.C.C.S.,</span></p>
<p style="top:284.3pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Istituto Neurologico Carlo Besta, 20133 Milan, Italy</span></p>
<p style="top:294.7pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">3</span></p>
<p style="top:296.4pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Department of Clinical, Internal, Anesthesiologic and Cardiovascular Sciences, Atherothrombosis Center,</span></p>
<p style="top:308.5pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">I Medical Clinic l, Sapienza University of Rome, 00161 Rome, Italy; francesco.delsole@uniroma1.it</span></p>
<p style="top:318.9pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">4</span></p>
<p style="top:320.6pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Oncology Department, Mario Negri Institute for Pharmacological Research I.R.C.C.S., 20156 Milan, Italy;</span></p>
<p style="top:332.7pt;left:97.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">veronicaandrea.&#xfb01;ttipaldo@marionegri.it</span></p>
<p style="top:343.2pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">5</span></p>
<p style="top:344.8pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Internal Medicine Department, ASST Great Metropolitan Hospital Niguarda, 20162 Milan, Italy;</span></p>
<p style="top:356.9pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">francesca.agnelli@ospedaleniguarda.it</span></p>
<p style="top:367.4pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">6</span></p>
<p style="top:369.0pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Department of Laboratory Medicine, ASST Great Metropolitan Hospital Niguarda, 20162 Milan, Italy;</span></p>
<p style="top:381.1pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">elvira.inglese@ospedaleniguarda.it</span></p>
<p style="top:391.6pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">7</span></p>
<p style="top:393.2pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Experimental &amp; Clinical Pharmacology Unit, Oncology Referral Center (CRO), IRCCS, 33081 Aviano, Italy</span></p>
<p style="top:403.7pt;left:82.2pt;line-height:7.0pt"><span style="font-family:URWPalladioL,serif;font-size:7.0pt">8</span></p>
<p style="top:405.3pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">SSD Diabetes Unit, ASST Great Metropolitan Hospital Niguarda, 20162 Milan, Italy;</span></p>
<p style="top:417.4pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">basilio.pintaudi@ospedaleniguarda.it</span></p>
<p style="top:429.5pt;left:81.4pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">*</span></b></p>
<p style="top:429.5pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Correspondence: danilo.menichelli@uniroma1.it</span></p>
<p style="top:441.7pt;left:82.2pt;line-height:9.0pt"><span style="font-family:Pxsy,serif;font-size:9.0pt">&#x2020;</span></p>
<p style="top:441.7pt;left:97.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">These authors equally contributed to this article.</span></p>
<p style="top:467.7pt;left:82.2pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Received: 16 October 2020; Accepted: 30 October 2020; Published: 3 November 2020</span></p>
<p style="top:459.6pt;left:487.1pt;line-height:7.9pt"><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span><span style="font-family:SourceSansRoman.613wght,serif;font-size:7.0pt">&#xfffd;</span></p>
<p style="top:466.8pt;left:487.1pt;line-height:7.9pt"><b><span style="font-family:SourceSansRoman,serif;font-size:7.9pt">&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;&#xfffd;</span></b></p>
<p style="top:491.0pt;left:81.8pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Abstract:</span></b><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> Liver lipid accumulation is a hallmark of non-alcoholic fatty liver disease (NAFLD),</span></p>
<p style="top:504.4pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">broadly associated with insulin resistance. Inositols (INS) are ubiquitous polyols implied in many</span></p>
<p style="top:517.9pt;left:81.9pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">physiological functions.</span></p>
<p style="top:517.9pt;left:199.3pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">They are produced endogenously, are present in many foods and in</span></p>
<p style="top:531.6pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">dietary supplements. Alterations in INS metabolism seems to play a role in diseases involving insulin</span></p>
<p style="top:545.1pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">resistance such as diabetes and polycystic ovary syndrome. Given its role in other metabolic syndromes,</span></p>
<p style="top:558.5pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the hypothesis of an INS role as a supplement in NAFLD is intriguing. We performed a systematic</span></p>
<p style="top:572.0pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">review of the literature to &#xfb01;nd preclinical and clinical evidence of INS supplementation e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cacy in</span></p>
<p style="top:585.6pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">NAFLD patients. We retrieved 10 studies on animal models assessing Myoinosiol or Pinitol de&#xfb01;ciency</span></p>
<p style="top:599.0pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">or supplementation and one human randomized controlled trial (RCT). Overall, INS de&#xfb01;ciency</span></p>
<p style="top:612.5pt;left:81.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">was associated with increased fatty liver in animals. Conversely, INS supplementation in animal</span></p>
<p style="top:626.0pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">models of fatty liver reduced hepatic triglycerides and cholesterol accumulation and maintained</span></p>
<p style="top:639.5pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a normal ultrastructural liver histopathology. In the one included RCT, Pinitol supplementation</span></p>
<p style="top:653.2pt;left:82.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">obtained similar results. Pinitol signi&#xfb01;cantly reduced liver fat, post-prandial triglycerides, AST levels,</span></p>
<p style="top:666.5pt;left:82.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">lipid peroxidation increasing glutathione peroxidase activity. These results, despite being limited,</span></p>
<p style="top:680.1pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">indicate the need for further evaluation of INS in NAFLD in larger clinical trials.</span></p>
<p style="top:705.6pt;left:82.2pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Keywords:</span></b></p>
<p style="top:705.5pt;left:141.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">non-alcoholic fatty liver disease; NAFLD; inositol; myoinositol; chiro-inositol;</span></p>
<p style="top:719.1pt;left:82.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">systematic review</span></p>
<p style="top:793.0pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379; doi:10.3390</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">nu12113379</span></p>
<p style="top:793.0pt;left:400.0pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">www.mdpi.com</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">journal</span><span style="font-family:Rpxr,serif;font-size:8.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt">nutrients</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">2 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">1. Introduction</span></b></p>
<p style="top:109.3pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Non-alcoholic fatty liver disease (NAFLD) is the most important emerging liver disease, and its</span></p>
<p style="top:122.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">rising incidence in di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent countries seems to partly explain the new chronic liver disease pandemic.</span></p>
<p style="top:136.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">In Italy, the incidence of NAFLD is 18.5 per 1000 person</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">years, and due to the high number of risk</span></p>
<p style="top:149.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">factors in these patients, its prevalence can increase up to 70% in subgroups of patients a</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ected by</span></p>
<p style="top:163.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">type 2 diabetes mellitus [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:176.9pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Non-alcoholic fatty liver disease burden does not only weigh on the liver, but is burdened by a</span></p>
<p style="top:190.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">series of cardiovascular, neurological, and kidney complications, making the treatment of this disease</span></p>
<p style="top:203.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">crucial for the improvement of both survival and quality of life in these patients. Non-alcoholic fatty</span></p>
<p style="top:217.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">liver disease patients have an increased risk of developing not only non-alcoholic steatohepatitis</span></p>
<p style="top:230.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(NASH), but also liver &#xfb01;brosis, liver cirrhosis, and hepatocellular carcinoma (HCC), albeit NAFLD,</span></p>
<p style="top:244.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">itself, being the third most common cause of liver transplantation [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">2</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. As a consequence of the cross-talk</span></p>
<p style="top:257.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">between metabolic liver disease and the cardiovascular system, NAFLD patients carry an increased</span></p>
<p style="top:271.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">risk of cardiovascular events [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">3</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], but more speci&#xfb01;cally they develop cumulative damage in several</span></p>
<p style="top:285.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tissues such as valves, myocardium, and conduction systems [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">4</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Chronic kidney disease also shows</span></p>
<p style="top:298.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">an association with NAFLD, and a more rapid decline of the glomerular &#xfb01;ltration rate was present in</span></p>
<p style="top:312.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">NAFLD patients [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">5</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:325.4pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Several treatments are still under study in order to prevent and slow down the progression of</span></p>
<p style="top:339.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">NAFLD, targeting several steps in the pathogenesis of the disease. Starting with diet, metabolic targets,</span></p>
<p style="top:352.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">such as peroxisome proliferator-activated receptor gamma (PPAR</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b3;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">6</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], and going through cell stress,</span></p>
<p style="top:366.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">apoptosis, oxidative stress, and immune response [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">7</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">], evidence for a structured treatment tailored to</span></p>
<p style="top:379.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the patient are still lacking.</span></p>
<p style="top:393.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Inositols (INS) are ubiquitous polyols implied in many physiological functions. They are produced</span></p>
<p style="top:406.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">endogenously, are present in many foods and are available as dietary supplements. Alterations in</span></p>
<p style="top:420.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">INS absorption, metabolism and excretion seems to play a role in metabolic diseases involving insulin</span></p>
<p style="top:433.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">resistance, recently the therapeutic role of INS in these diseases is gaining more attention and showing</span></p>
<p style="top:447.1pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">potential bene&#xfb01;ts.</span></p>
<p style="top:460.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The aim of this paper was to discuss the potential role of INS in NAFLD and their potential as</span></p>
<p style="top:474.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">therapeutic agents to attenuate the metabolic cascade that leads to the progression of liver disease.</span></p>
<p style="top:487.5pt;left:76.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">We will provide a general overview of the physiopathological role of INS in humans and their</span></p>
<p style="top:501.1pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pharmacological properties as well as a systematic review of the available preclinical and clinical</span></p>
<p style="top:514.6pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">evidence regarding INS de&#xfb01;ciency and supplementation in NAFLD.</span></p>
<p style="top:537.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">2. Biological Role of Inositol and Its Derivates</span></b></p>
<p style="top:557.3pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Inositols are 6-carbon sugar alcohols. There are 9 INS isomers (Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">) di</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ering one from the</span></p>
<p style="top:570.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">other on the basis of the spatial orientation of the hydroxyl groups.</span></p>
<p style="top:584.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The most common form is myoinositol (MI) which is present in animals, plant cells, and in</span></p>
<p style="top:598.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">foods [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">8</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Myoinositol can be found in free form, as inositol-associated phospholipid and as phosphate</span></p>
<p style="top:611.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">or pyrophosphate INS derivatives (e.g., inositol hexaphosphate or phytic acid and derived diphosphates</span></p>
<p style="top:624.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and inositol trisphosphate). Phytic acid has a fundamental role as a storage form of phosphorus</span></p>
<p style="top:638.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in plants. Bran and seeds are particularly rich in MI, and beans and peas contain high amounts of</span></p>
<p style="top:651.8pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">phytic acid as vegetables. Myoinositol can be synthetized de novo endogenously from D-glucose:</span></p>
<p style="top:665.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">this biosynthesis of MI in humans occurs predominantly in kidneys, though other tissues can also</span></p>
<p style="top:679.0pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">produce it. Myoinositol catabolism also takes place in kidneys, through the oxidation to D-glucuronic</span></p>
<p style="top:692.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">acid. In addition, kidneys play and important role in the regulation of INS plasmatic concentrations.</span></p>
<p style="top:705.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Inositol has many key functions in biological systems. It plays a very important structural</span></p>
<p style="top:719.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">role in eukaryotic cells serving as a secondary messenger, particularly in the form of inositol</span></p>
<p style="top:732.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">trisphosphate (IP3) and phosphatidylinositol phosphate lipids (PIP2 or PIP3) and INS glycans.</span></p>
<p style="top:746.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Membrane phosphatidylinositol are fundamental in cell response to external stimuli such as hormones</span></p>
<p style="top:759.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and neurotransmitters. The best studied mechanism of response to stimulation is the IP3-mediated</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">3 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cytosolic release of calcium from the endoplasmic reticulum [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">9</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Inositol trisphosphate is responsible</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">for the regulation of the activity of hormones such as insulin, follicle-stimulating hormone (FSH),</span></p>
<p style="top:117.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and thyroid stimulating hormone (TSH) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">10</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">12</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Furthermore, MI is responsible for oocyte maturation</span></p>
<p style="top:130.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and is involved also in several functions of the male reproductive system [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">13</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In addition to the</span></p>
<p style="top:144.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">classic insulin signaling pathway involving phosphoinositide 3 kinase (PI3K) and protein kinase B</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Akt</span></p>
<p style="top:157.4pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">(PBK</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Akt) as second messengers, a complementary pathway involving INS phosphoglycans (IPGs)</span></p>
<p style="top:171.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">exists [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. After the stimulation of insulin, phospholipase C causes the liberation of IPGs, which acts</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">as an insulin-mimetic secondary messenger in response to insulin stimulation, promoting GLUT-4</span></p>
<p style="top:198.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">translocation, glucose uptake, and glycogen synthase [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">15</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:203.6pt;left:87.6pt;line-height:7.6pt"><i><span style="font-family:Palatino Linotype,Italic,serif;font-size:7.6pt">Nutrients </span></i><b><span style="font-family:Palatino Linotype,Bold,serif;font-size:7.6pt">2020</span></b><span style="font-family:Palatino Linotype,serif;font-size:7.6pt">, </span><i><span style="font-family:Palatino Linotype,Italic,serif;font-size:7.6pt">12</span></i><span style="font-family:Palatino Linotype,serif;font-size:7.6pt">, x FOR PEER REVIEW </span></p>
<p style="top:203.6pt;left:485.8pt;line-height:7.6pt"><span style="font-family:Palatino Linotype,serif;font-size:7.6pt">3 of 13 </span></p>
<p style="top:452.4pt;left:508.0pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt"> </span></p>
<p style="top:468.6pt;left:107.8pt;line-height:8.6pt"><b><span style="font-family:Palatino Linotype,Bold,serif;font-size:8.6pt">Figure 1. </span></b><span style="font-family:Palatino Linotype,serif;font-size:8.6pt">Inositol stereoisomers. Myo-, D-chiro-, L-chiro, Muco-, Scyllo-, and Neo- are the isomers </span></p>
<p style="top:481.0pt;left:107.8pt;line-height:8.6pt"><span style="font-family:Palatino Linotype,serif;font-size:8.6pt">naturally found in plants and animals. Allo-, cis-, and epi- stereoisomers are the synthetically obtained </span></p>
<p style="top:493.3pt;left:107.8pt;line-height:8.6pt"><span style="font-family:Palatino Linotype,serif;font-size:8.6pt">compounds. </span></p>
<p style="top:516.5pt;left:107.8pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">The most common form is myoinositol (MI) which is present in animals, plant cells, and in foods </span></p>
<p style="top:529.3pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Times New Roman,serif;font-size:9.5pt">[8]</span><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">. Myoinositol can be found in free form, as inositol-associated phospholipid and as phosphate or </span></p>
<p style="top:542.2pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">pyrophosphate INS derivatives (e.g., inositol hexaphosphate or phytic acid and derived </span></p>
<p style="top:554.9pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">diphosphates and inositol trisphosphate). Phytic acid has a fundamental role as a storage form of </span></p>
<p style="top:567.8pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">phosphorus in plants. Bran and seeds are particularly rich in MI, and beans and peas contain high </span></p>
<p style="top:580.6pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">amounts of phytic acid as vegetables. Myoinositol can be synthetized de novo endogenously from D-</span></p>
<p style="top:593.4pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">glucose: this biosynthesis of MI in humans occurs predominantly in kidneys, though other tissues </span></p>
<p style="top:606.2pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">can also produce it. Myoinositol catabolism also takes place in kidneys, through the oxidation to D-</span></p>
<p style="top:619.1pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">glucuronic acid. In addition, kidneys play and important role in the regulation of INS plasmatic </span></p>
<p style="top:631.9pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">concentrations. </span></p>
<p style="top:644.7pt;left:107.8pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">Inositol has many key functions in biological systems. It plays a very important structural role </span></p>
<p style="top:657.5pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">in eukaryotic cells serving as a secondary messenger, particularly in the form of inositol trisphosphate </span></p>
<p style="top:670.3pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">(IP3) and phosphatidylinositol phosphate lipids (PIP2 or PIP3) and INS glycans. Membrane </span></p>
<p style="top:683.1pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">phosphatidylinositol are fundamental in cell response to external stimuli such as hormones and </span></p>
<p style="top:696.0pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">neurotransmitters. The best studied mechanism of response to stimulation is the IP3-mediated </span></p>
<p style="top:708.8pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">cytosolic release of calcium from the endoplasmic reticulum [9]. Inositol trisphosphate is responsible </span></p>
<p style="top:721.6pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">for the regulation of the activity of hormones such as insulin, follicle-stimulating hormone</span><span style="font-family:Palatino Linotype,serif;font-size:9.5pt;color:#4d5155"> </span><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">(FSH), and </span></p>
<p style="top:734.4pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">thyroid stimulating hormone (TSH) [10</span><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">&#x2013;</span><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">12]. Furthermore, MI is responsible for oocyte maturation </span></p>
<p style="top:747.2pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">and is involved also in several functions of the male reproductive system [13]. In addition to the </span></p>
<p style="top:760.0pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">classic insulin signaling pathway involving phosphoinositide 3 kinase (PI3K) and protein kinase </span></p>
<p style="top:772.8pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">B/Akt (PBK/Akt) as second messengers, a complementary pathway involving INS phosphoglycans </span></p>
<p style="top:785.7pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">(IPGs) exists [14]. After the stimulation of insulin, phospholipase C causes the liberation of IPGs, </span></p>
<p style="top:798.5pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">which acts as an insulin-mimetic secondary messenger in response to insulin stimulation, promoting </span></p>
<p style="top:811.3pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">GLUT-4 translocation, glucose uptake, and glycogen synthase [15]. </span></p>
<p style="top:824.1pt;left:107.8pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">Despite MI being the most abundant INS isoform, a second important active isomer is D-chiro-</span></p>
<p style="top:836.9pt;left:87.6pt;line-height:9.5pt"><span style="font-family:Palatino Linotype,serif;font-size:9.5pt">inositol (DCI) which is a derivative of MI formed via inversion in the configuration of hydroxyls</span></p>
<img style="position:absolute;transform:matrix(.43759377,0,-0,.43763335,-243.15894,95.44403)" src="data:image/png;base64,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">
<p style="top:471.8pt;left:97.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Inositol stereoisomers. Myo-, D-chiro-, L-chiro, Muco-, Scyllo-, and Neo- are the isomers</span></p>
<p style="top:484.6pt;left:97.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">naturally found in plants and animals.</span></p>
<p style="top:484.6pt;left:268.4pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Allo-, cis-, and epi- stereoisomers are the synthetically</span></p>
<p style="top:497.5pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">obtained compounds.</span></p>
<p style="top:518.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Despite MI being the most abundant INS isoform, a second important active isomer is</span></p>
<p style="top:531.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">D-chiro-inositol (DCI), which is a derivative of MI, formed via inversion in the con&#xfb01;guration of</span></p>
<p style="top:545.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">hydroxyls performed by the insulin-dependent enzyme NAD</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">NADH epimerase [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">16</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The epimerase</span></p>
<p style="top:558.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">acts upon insulin stimulation.</span></p>
<p style="top:572.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The liberation of IPGs by the phospholipase C mediates the release of IPGs containing both MI or</span></p>
<p style="top:585.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">DCI, which promotes the activation of di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent enzymes: DCI stimulates pyruvate dehydrogenase</span></p>
<p style="top:599.5pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">phosphatase, while MI inhibits protein kinase A and adenylyl cyclase [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Myoinositol levels are higher</span></p>
<p style="top:612.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in tissues utilizing large amounts of glucose such as the brain, heart, and ovaries. D-chiro-inositol is</span></p>
<p style="top:626.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">more prevalent in tissues requiring glucose storage such as liver and muscles. In insulin-resistance</span></p>
<p style="top:639.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">conditions, MI epimerization is impaired in muscles, fat, and liver, and a correlation between the</span></p>
<p style="top:653.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">degree of insulin resistance and reduction in the DCI</span><span style="font-family:Rpxr,serif;font-size:10.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">MI ratio was observed.</span></p>
<p style="top:666.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Furthermore, in patients a</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ected by insulin resistance, diabetes, and metabolic syndrome,</span></p>
<p style="top:680.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">a decreased availability of MI has been observed due to the increased MI urinary loss caused by</span></p>
<p style="top:693.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the glucose-mediated inhibition of MI reabsorption in the kidney, while DCI urinary levels are</span></p>
<p style="top:707.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">reduced [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">17</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">18</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:721.0pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The role of INS in insulin resistance is still not completely understood. It is not clear if it depends</span></p>
<p style="top:734.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">on a reduction in the membrane availability of IPGs or an impairment in the epimerase activation.</span></p>
<p style="top:748.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">However, many studies have demonstrated the bene&#xfb01;cial role of INS in conditions with underlying</span></p>
<p style="top:761.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">insulin resistance [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">19</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">4 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">3. Inositol Pharmacology</span></b></p>
<p style="top:109.4pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Inositol is absorbed in the small intestine, and time plasma concentration after oral administration</span></p>
<p style="top:122.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">is obtained at 4 h (T</span><span style="font-family:URWPalladioL,serif;font-size:7.6pt">max</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">25</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Maximal plasma concentration (C</span><span style="font-family:URWPalladioL,serif;font-size:7.6pt">max</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">) is 36&#x2013;45 mcg [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">26</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Inositol is</span></p>
<p style="top:136.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">actively transported by intestinal cells via a Na</span><span style="font-family:Rpxr,serif;font-size:10.0pt"> +</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> dependent transporter, and glucose is able to a</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect</span></p>
<p style="top:150.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">this process through a non-competitive mechanism. Intestinal absorption of INS is in&#xfb02;uenced by lipids;</span></p>
<p style="top:163.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">thus, the pharmaceutical form in soft gel capsules has a better bioavailability than powder [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">27</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:176.8pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">As dietary supplements, MI and DCI are well tolerated. Despite the shortage of direct toxicity</span></p>
<p style="top:190.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">studies, safety of INS supplementation in humans has been analyzed in several preclinical and</span></p>
<p style="top:203.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">clinical studies at doses ranging from 4 to 12 g</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">day. Gastrointestinal adverse e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ects have been</span></p>
<p style="top:217.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">reported in the literature with an incidence of 5% at doses of 12 g</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">day or higher [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">28</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. In a limited</span></p>
<p style="top:231.0pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">population of patients with psychiatric disorders, mild neurological drug-related adverse e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects have</span></p>
<p style="top:244.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">been observed [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">29</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. A review of &#xfb01;ve RCTs evaluating the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy of INS supplementation during</span></p>
<p style="top:257.9pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pregnancy for the prevention of gestational diabetes (GDM) reported a bene&#xfb01;cial e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect on GDM</span></p>
<p style="top:271.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">incidence and preterm delivery rate, with no reported adverse events (411 patients included) [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">30</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:284.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Furthermore, INS administration at the dose of 4 g</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">day has not received any reports of adverse</span></p>
<p style="top:298.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">events during clinical studies so far [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">31</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Inositol supplementation has shown to be e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ective in</span></p>
<p style="top:311.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">treating di</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">erent diseases. Several studies have reported positive e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of INS supplementation in</span></p>
<p style="top:325.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">fasting blood glucose improvement and HbA1c [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">20</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">32</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Also, GDM, MI or DCI supplementation</span></p>
<p style="top:339.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">has provided encouraging results, positively a</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ecting maternal fetal outcomes and reducing glucose</span></p>
<p style="top:352.5pt;left:76.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">variability [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">33</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">34</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Another syndrome which seems to possibly bene&#xfb01;t from INS supplementation is</span></p>
<p style="top:366.0pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">polycystic ovary syndrome (PCOS), where MI demonstrated results similar to metformin in terms of</span></p>
<p style="top:379.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">homeostatic model assessment-insulin resistance (HOMA-IR) reduction and other metabolic outcomes</span></p>
<p style="top:393.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">such as BMI and menstrual cycle improvement [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">10</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">24</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">35</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:416.3pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4. Systematic Review Methods</span></b></p>
<p style="top:439.5pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.1. Eligibility Criteria</span></i></p>
<p style="top:459.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">We included all original clinical research articles in English with the full-text available. In particular,</span></p>
<p style="top:472.6pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">we included all studies that investigated the role of INS, as Mesoinositol, Myoinositol or Chiro-inositol,</span></p>
<p style="top:485.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">de&#xfb01;ciency or supplementation in preclinical</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vitro</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> or</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> models as well as in clinical settings</span></p>
<p style="top:499.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">in patients with non-alcoholic fatty liver disease. We did not include the following: (1) case reports,</span></p>
<p style="top:513.1pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">editorials</span><span style="font-family:Rpxr,serif;font-size:9.9pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">comments, letters; (2) subgroup analyses from the same clinical trial; (3) studies not addressing</span></p>
<p style="top:526.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">study questions, (4) reviews or meta-analysis.</span></p>
<p style="top:549.7pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.2. Information Sources and Search Strategy</span></i></p>
<p style="top:569.2pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">We performed a systematic review of the literature searching MEDLINE via PubMed, EMBASE,</span></p>
<p style="top:582.7pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">and Cochrane Library for a combination of the following keywords: &#x201c;inositol&#x201d;, &#x201c;mesoinositol&#x201d;,</span></p>
<p style="top:596.2pt;left:75.0pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">&#x201c;myoinositol&#x201d;, &#x201c;chiro-inositol&#x201d;, &#x201c;non-alcoholic fatty liver disease&#x201d;, &#x201c;NAFLD&#x201d;, &#x201c;Nonalcoholic Fatty</span></p>
<p style="top:609.8pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Liver Disease&#x201d;, &#x201c;fatty liver nonalcoholic&#x201d;, &#x201c;Nonalcoholic Fatty Livers&#x201d;, &#x201c;Nonalcoholic Steatohepatitis&#x201d;,</span></p>
<p style="top:623.3pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">and &#x201c;steatohepatitis nonalcoholic&#x201d;. References of included articles were searched for other publications</span></p>
<p style="top:636.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">relevant to the present review. The research strategy (Supplementary Materials File S1) was performed</span></p>
<p style="top:650.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">according to PRISMA guidelines with no time restriction until 9 October 2020.</span></p>
<p style="top:673.5pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.3. Study Selection</span></i></p>
<p style="top:692.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">The study selection was performed in multiple phases. In the &#xfb01;rst phase, potentially relevant</span></p>
<p style="top:706.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">studies were obtained by combined searches of electronic databases using the selected abovementioned</span></p>
<p style="top:719.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">keywords. Then, studies not in English, with no abstract</span><span style="font-family:Rpxr,serif;font-size:10.1pt">/</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">full text were excluded. In the second</span></p>
<p style="top:733.4pt;left:76.2pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">phase, studies were reviewed and excluded by study typology; thus, letters, editorials, case reports,</span></p>
<p style="top:747.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and comments were excluded. The third phase consisted of a detailed analysis of full-text articles to</span></p>
<p style="top:760.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">assess whether they addressed the speci&#xfb01;c study question.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">5 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.4. Data Collection Process and Data Items</span></i></p>
<p style="top:109.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">All authors independently screened the titles and abstracts of manuscripts identi&#xfb01;ed through</span></p>
<p style="top:122.8pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">the database searches to identify studies potentially eligible for further assessment. For each study,</span></p>
<p style="top:136.3pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">we collected the following information: authors, year of publication, study typology, study aim,</span></p>
<p style="top:149.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">main results, and INS evaluated.</span></p>
<p style="top:173.1pt;left:76.5pt;line-height:10.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:10.0pt">4.5. Ethical Review</span></i></p>
<p style="top:192.6pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Given the study type (i.e., review article), ethical approval was not necessary.</span></p>
<p style="top:215.8pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">5. Results</span></b></p>
<p style="top:235.2pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">After duplicates removal, a total of 76 references were screened by title and abstract. Overall,</span></p>
<p style="top:248.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">73 references were excluded with reason (Figure</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 2</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">). Three studies (one animal de&#xfb01;ciency, one animal</span></p>
<p style="top:262.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">supplementation, and human supplementation trial) were included. After the revision of references of</span></p>
<p style="top:275.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">included studies, an additional six studies assessing animal supplementation and two assessing animal</span></p>
<p style="top:289.4pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">de&#xfb01;ciency were retrieved. A total of 11 studies were included in our systematic review. Included study</span></p>
<p style="top:302.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">characteristics are presented in Table</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7"> 1</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">.</span></p>
<p style="top:307.0pt;left:85.9pt;line-height:8.0pt"><i><span style="font-family:Palatino Linotype,Italic,serif;font-size:8.0pt">Nutrients </span></i><b><span style="font-family:Palatino Linotype,Bold,serif;font-size:8.0pt">2020</span></b><span style="font-family:Palatino Linotype,serif;font-size:8.0pt">, </span><i><span style="font-family:Palatino Linotype,Italic,serif;font-size:8.0pt">12</span></i><span style="font-family:Palatino Linotype,serif;font-size:8.0pt">, x FOR PEER REVIEW </span></p>
<p style="top:307.0pt;left:505.2pt;line-height:8.0pt"><span style="font-family:Palatino Linotype,serif;font-size:8.0pt">7 of 13 </span></p>
<p style="top:644.0pt;left:523.3pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt"> </span></p>
<p style="top:661.0pt;left:256.7pt;line-height:9.0pt"><b><span style="font-family:Palatino Linotype,Bold,serif;font-size:9.0pt">Figure 2. </span></b><span style="font-family:Palatino Linotype,serif;font-size:9.0pt">Study selection. </span></p>
<p style="top:685.5pt;left:85.9pt;line-height:10.0pt"><b><span style="font-family:Palatino Linotype,Bold,serif;font-size:10.0pt">6. Inositol Deficiency in NAFLD </span></b></p>
<p style="top:705.0pt;left:107.2pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">Non-alcoholic fatty liver disease is now considered as a hepatic component of the metabolic </span></p>
<p style="top:718.5pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">syndrome and, although its incidence is still rising, no specific therapies are actually available. Over </span></p>
<p style="top:732.0pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">the last decades, some nutraceuticals, such as vitamin C and E, silymarin, flavonoids or resveratrol, </span></p>
<p style="top:745.5pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">were raised as potential treatments for NAFLD by reducing oxidative stress, inflammation, and </span></p>
<p style="top:759.0pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">insulin resistance [47</span><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">50]. However, these treatments counteract the pathological effects of the fatty </span></p>
<p style="top:772.5pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">liver but do not target specific metabolic and signal transduction pathways. </span></p>
<p style="top:786.0pt;left:107.2pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">Rather, a potential preventive role on NAFLD may be represented by INS. Indeed, the lack of </span></p>
<p style="top:799.5pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">INS and its compounds may worsen the fatty liver disease as shown in a zebrafish model, in which </span></p>
<p style="top:813.0pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">a reduction of phosphatidylinositol synthesis increased endoplasmic reticulum stress and, </span></p>
<p style="top:826.5pt;left:85.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">consequently, hepatic steatosis [38]. The role of INS in preventing the development of NAFLD is </span></p>
<p style="top:839.9pt;left:96.6pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">h</span></p>
<p style="top:839.9pt;left:122.5pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">d i</span></p>
<p style="top:839.9pt;left:151.8pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">t</span></p>
<p style="top:839.9pt;left:173.0pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">h</span></p>
<p style="top:839.9pt;left:195.2pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">th</span></p>
<p style="top:839.9pt;left:220.1pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">ithd</span></p>
<p style="top:839.9pt;left:260.4pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">l</span></p>
<p style="top:839.9pt;left:271.6pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">f INS</span></p>
<p style="top:839.9pt;left:341.3pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">i t d</span></p>
<p style="top:839.9pt;left:374.4pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">ith th</span></p>
<p style="top:839.9pt;left:426.2pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">t</span></p>
<p style="top:839.9pt;left:437.6pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">f NAFLD</span></p>
<p style="top:839.9pt;left:508.9pt;line-height:10.0pt"><span style="font-family:Palatino Linotype,serif;font-size:10.0pt">i ll</span></p>
<img style="position:absolute;transform:matrix(.48006664,0,-0,.48017777,-190.66132,203.21332)" src="data:image/jpeg;base64,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==">
<p style="top:663.9pt;left:247.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Figure 2.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Study selection.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">6 of 13</span></p>
<p style="top:89.7pt;left:246.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Included studies.</span></p>
<p style="top:110.8pt;left:82.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Study</span></b></p>
<p style="top:110.8pt;left:163.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Year</span></b></p>
<p style="top:110.8pt;left:209.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Evaluated INS</span></b></p>
<p style="top:110.8pt;left:283.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Study Characteristics</span></b></p>
<p style="top:110.8pt;left:400.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Main Results</span></b></p>
<p style="top:126.5pt;left:82.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Animal Studies&#x2014;De&#xfb01;ciency</span></b></p>
<p style="top:142.3pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hayashi [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:142.3pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1974</span></p>
<p style="top:142.3pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI</span></p>
<p style="top:142.3pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rats fed with an</span></p>
<p style="top:153.2pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI-de&#xfb01;cient diet or the</span></p>
<p style="top:164.2pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">same diet with the</span></p>
<p style="top:175.2pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">addition of 0.5% MI for up</span></p>
<p style="top:186.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">to &#xfb01;ve weeks.</span></p>
<p style="top:142.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Increased levels of liver TG,</span></p>
<p style="top:153.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CE, and non-esteri&#xfb01;ed fatty</span></p>
<p style="top:164.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">acids and concomitant</span></p>
<p style="top:175.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increase in serum</span></p>
<p style="top:186.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">non-esteri&#xfb01;ed fatty acids in</span></p>
<p style="top:197.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">the MI-de&#xfb01;cient group.</span></p>
<p style="top:214.0pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hayashi [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:214.0pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1974</span></p>
<p style="top:214.0pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI</span></p>
<p style="top:214.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rats fed with an</span></p>
<p style="top:225.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI-de&#xfb01;cient diet or the</span></p>
<p style="top:235.9pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">same diet with the</span></p>
<p style="top:246.9pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">addition of 0.5% MI for</span></p>
<p style="top:257.9pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">one or two weeks.</span></p>
<p style="top:214.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Liver TG levels were</span></p>
<p style="top:225.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increased in MI-de&#xfb01;cient</span></p>
<p style="top:235.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">rats, especially in palmitic,</span></p>
<p style="top:246.9pt;left:400.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">palmitoleic, and oleic acids.</span></p>
<p style="top:274.8pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Thakur [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:274.8pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2011</span></p>
<p style="top:274.8pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PI</span></p>
<p style="top:274.8pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zebra&#xfb01;sh mutants</span></p>
<p style="top:285.8pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">incapable of PI synthesis.</span></p>
<p style="top:274.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mutants exhibited</span></p>
<p style="top:285.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">hepatomegaly with</span></p>
<p style="top:296.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">microscopic NAFLD</span></p>
<p style="top:307.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">features with upregulated</span></p>
<p style="top:318.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">endoplasmic reticulum</span></p>
<p style="top:329.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">stress markers.</span></p>
<p style="top:345.3pt;left:82.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Animal Studies&#x2014;Supplementation</span></b></p>
<p style="top:361.1pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Katayama [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:361.1pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1994</span></p>
<p style="top:361.1pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI</span></p>
<p style="top:361.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rats fed with either corn</span></p>
<p style="top:372.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">starch or a high-sucrose</span></p>
<p style="top:383.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diet, with or without MI,</span></p>
<p style="top:394.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">for 16&#x2013;17 days.</span></p>
<p style="top:361.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Reduction in the increase of</span></p>
<p style="top:372.1pt;left:400.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">liver weight, total lipids, TG,</span></p>
<p style="top:383.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and CE by MI in</span></p>
<p style="top:394.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">high-sucrose fed rats;</span></p>
<p style="top:404.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduction in serum TG</span></p>
<p style="top:415.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increase in the same group.</span></p>
<p style="top:432.8pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Katayama [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:432.8pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1997</span></p>
<p style="top:432.8pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI, sodium</span></p>
<p style="top:443.8pt;left:208.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phytate</span></p>
<p style="top:432.8pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rats fed with either corn</span></p>
<p style="top:443.8pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">starch or a high-sucrose</span></p>
<p style="top:454.8pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diet, with or without the</span></p>
<p style="top:465.7pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">addition of MI or sodium</span></p>
<p style="top:476.7pt;left:282.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phytate for 12&#x2013;13 days.</span></p>
<p style="top:432.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI and sodium phytate</span></p>
<p style="top:443.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced liver enlargement</span></p>
<p style="top:454.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and suppressed to normal</span></p>
<p style="top:465.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">levels liver TG and total</span></p>
<p style="top:476.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">lipids levels; reduced liver</span></p>
<p style="top:487.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">G6PD, ME, and FASN.</span></p>
<p style="top:504.6pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Geethan [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:504.6pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2008</span></p>
<p style="top:504.6pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol</span></p>
<p style="top:504.6pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Streptozotocin-induced</span></p>
<p style="top:515.5pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diabetic rats treated with</span></p>
<p style="top:526.5pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">or without 100 mg</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">kg</span></p>
<p style="top:537.4pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol for 30 days.</span></p>
<p style="top:504.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol reduced blood</span></p>
<p style="top:515.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glucose and serum TG, free</span></p>
<p style="top:526.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">fatty acids, and CE;</span></p>
<p style="top:537.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">decreased TG and CE liver</span></p>
<p style="top:548.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">concentration; decreased the</span></p>
<p style="top:559.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">concentration of liver</span></p>
<p style="top:570.3pt;left:400.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phospholipids and free fatty</span></p>
<p style="top:581.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">acids; increased HDL and</span></p>
<p style="top:592.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced LDL.</span></p>
<p style="top:609.2pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zhou [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:609.2pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2008</span></p>
<p style="top:609.2pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol</span></p>
<p style="top:609.2pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rats fed with a high-fat</span></p>
<p style="top:620.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diet for 8 weeks, with or</span></p>
<p style="top:631.1pt;left:282.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">without 0.1%, 1.0%, or</span></p>
<p style="top:642.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2.0% Pinitol, and induced</span></p>
<p style="top:653.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">hepatic injury by a single</span></p>
<p style="top:664.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">administration of GalN.</span></p>
<p style="top:609.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">After GalN administration,</span></p>
<p style="top:620.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol suppressed the</span></p>
<p style="top:631.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increase in ALT and AST;</span></p>
<p style="top:642.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">attenuated liver CE increase;</span></p>
<p style="top:653.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced TNF</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> levels;</span></p>
<p style="top:664.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced lipid peroxidation;</span></p>
<p style="top:674.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increased glutathione levels;</span></p>
<p style="top:685.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increased liver catalase;</span></p>
<p style="top:696.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Mn&#x2013;SOD; GR activities.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">7 of 13</span></p>
<p style="top:89.7pt;left:270.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Table 1.</span></b><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cont.</span></i></p>
<p style="top:110.8pt;left:82.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Study</span></b></p>
<p style="top:110.8pt;left:163.8pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Year</span></b></p>
<p style="top:110.8pt;left:209.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Evaluated INS</span></b></p>
<p style="top:110.8pt;left:283.0pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Study Characteristics</span></b></p>
<p style="top:110.8pt;left:400.3pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Main Results</span></b></p>
<p style="top:126.5pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Choi [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:126.5pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2009</span></p>
<p style="top:126.5pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol</span></p>
<p style="top:126.5pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hamsters fed with a</span></p>
<p style="top:137.5pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">high-fat, high-cholesterol</span></p>
<p style="top:148.4pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diet with or without 0.05%</span></p>
<p style="top:159.4pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">or 0.1% Pinitol for 10</span></p>
<p style="top:170.4pt;left:282.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">weeks.</span></p>
<p style="top:126.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol reduced epididymal</span></p>
<p style="top:137.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and perirenal white adipose</span></p>
<p style="top:148.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tissue; reduced plasma total</span></p>
<p style="top:159.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">CE, non-HDL CE, glucose,</span></p>
<p style="top:170.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and total-CE</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">HDL ratio;</span></p>
<p style="top:181.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced liver TG and CE;</span></p>
<p style="top:192.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">lowered HMGR and ACAT</span></p>
<p style="top:203.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">activities; suppression of</span></p>
<p style="top:214.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">liver lipid accumulation and</span></p>
<p style="top:225.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduction in adipocyte size.</span></p>
<p style="top:242.1pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Sivakumar [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:242.1pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2010</span></p>
<p style="top:242.1pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol</span></p>
<p style="top:242.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Streptozotocin-induced</span></p>
<p style="top:253.1pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diabetic rats treated with</span></p>
<p style="top:264.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol, gliclazide, or</span></p>
<p style="top:275.0pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">neither for 30 days.</span></p>
<p style="top:242.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Both Pinitol and gliclazide</span></p>
<p style="top:253.1pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reversed increase in blood</span></p>
<p style="top:264.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">glucose and glycosylated</span></p>
<p style="top:275.0pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hgb; reduced blood TNF-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:285.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">IL-6, and IL-1</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">; reduced</span></p>
<p style="top:296.9pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">liver peroxides and</span></p>
<p style="top:307.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">hydroperoxides; contrasted</span></p>
<p style="top:318.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">the diabetes-induced</span></p>
<p style="top:329.8pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">microscopic liver alterations</span></p>
<p style="top:340.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">normalizing the</span></p>
<p style="top:351.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tissue architecture.</span></p>
<p style="top:368.6pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Shimada [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:368.6pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2019</span></p>
<p style="top:368.6pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI</span></p>
<p style="top:368.6pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Rats fed with either a</span></p>
<p style="top:379.6pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">high-glucose or</span></p>
<p style="top:390.5pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">high-fructose diet, with or</span></p>
<p style="top:401.5pt;left:282.7pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">without MI 0.05% or 0.25%</span></p>
<p style="top:412.5pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">supplementation for 15</span></p>
<p style="top:423.4pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">days.</span></p>
<p style="top:368.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">MI dose-dependent</span></p>
<p style="top:379.7pt;left:400.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">reduction of liver TG content</span></p>
<p style="top:390.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and expression levels of</span></p>
<p style="top:401.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">G6PD, ME1, FASN, ACC</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:412.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and S14 in fatty liver</span></p>
<p style="top:423.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">high-fructose induced rats;</span></p>
<p style="top:434.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduction in hepatic</span></p>
<p style="top:445.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ChREBP</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> expression;</span></p>
<p style="top:456.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduction in ChREBP</span></p>
<p style="top:467.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">binding to the ChoRE</span></p>
<p style="top:478.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ChREBP</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b2;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> and FASN genes.</span></p>
<p style="top:494.0pt;left:82.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Human Studies&#x2014;Supplementation</span></b></p>
<p style="top:509.7pt;left:82.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Lee [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:509.7pt;left:163.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2019</span></p>
<p style="top:509.7pt;left:209.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol</span></p>
<p style="top:509.7pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Double-blind RCT on 90</span></p>
<p style="top:520.7pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">NAFLD patients taking</span></p>
<p style="top:531.6pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol 600 mg, 1000 mg or</span></p>
<p style="top:542.6pt;left:283.0pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">PBO for 12 weeks</span></p>
<p style="top:509.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">No signi&#xfb01;cant between</span></p>
<p style="top:520.7pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">groups di</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">erences in liver</span></p>
<p style="top:531.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">fat content at 12 weeks;</span></p>
<p style="top:542.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">signi&#xfb01;cant reduction in liver</span></p>
<p style="top:553.6pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">fat content in the 600 mg</span></p>
<p style="top:564.6pt;left:400.3pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">arm compared to its baseline.</span></p>
<p style="top:575.5pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pinitol signi&#xfb01;cantly reduced</span></p>
<p style="top:586.4pt;left:399.9pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">AST levels at 12 weeks;</span></p>
<p style="top:597.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced lipid peroxidation</span></p>
<p style="top:608.4pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">in terms of urinary MDA</span></p>
<p style="top:619.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">stability compared to PBO</span></p>
<p style="top:630.3pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">increased GPx. Pinitol</span></p>
<p style="top:641.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reduced blood TG increase</span></p>
<p style="top:652.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">after postprandial high-fat</span></p>
<p style="top:663.2pt;left:400.3pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">formula compared to PBO.</span></p>
<p style="top:678.4pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">INS</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> inositol; MI</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> myoinositol; PI</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> phosphatidylinositol; TG</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> triglycerides; GalN</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> D-galactosamine; ALT</span></p>
<p style="top:687.8pt;left:97.8pt;line-height:8.0pt"><span style="font-family:Rpxr,serif;font-size:8.0pt">=</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> alanine aminotransferase; AST</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> aspartate aminotransferase; TNF</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> tumor necrosis factor alpha; Mn&#x2013;SOD</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span></p>
<p style="top:697.4pt;left:97.8pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">MN-superoxide dismutase; GR</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> glutathione reductase; CE</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> cholesterol; HMGR</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> HMG-CoA-Reductase; ACAT</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span></p>
<p style="top:706.8pt;left:97.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">acyl-CoA cholesterol acetyltransferase; Hgb</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> hemoglobin; G6PD</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> glucose-6-phosphate-dehydrogenase; ME1</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span></p>
<p style="top:716.3pt;left:97.8pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">malic enzyme 1; FASN</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> fatty acid synthase; ACC</span><span style="font-family:EURM10,serif;font-size:8.0pt">&#x3b1;</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> acetyl-CoA-carboxylase alpha; S14</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> modulator of fatty acid</span></p>
<p style="top:725.8pt;left:97.8pt;line-height:7.9pt"><span style="font-family:URWPalladioL,serif;font-size:7.9pt">synthesis; ChREBP</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> carbohydrate-responsive element-binding protein; RCT</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:7.9pt"> randomized controlled trial; PBO</span><span style="font-family:Rpxr,serif;font-size:7.9pt"> =</span></p>
<p style="top:735.2pt;left:97.6pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">placebo; MDA</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> malondialdehyde; GPx</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> glutathione peroxidase; non-alcoholic fatty liver disease</span><span style="font-family:Rpxr,serif;font-size:8.0pt"> =</span><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> NAFLD.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">8 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">6. Inositol De&#xfb01;ciency in NAFLD</span></b></p>
<p style="top:109.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Non-alcoholic fatty liver disease is now considered as a hepatic component of the metabolic</span></p>
<p style="top:123.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">syndrome and, although its incidence is still rising, no speci&#xfb01;c therapies are actually available. Over the</span></p>
<p style="top:136.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">last decades, some nutraceuticals, such as vitamin C and E, silymarin, &#xfb02;avonoids or resveratrol,</span></p>
<p style="top:150.0pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">were raised as potential treatments for NAFLD by reducing oxidative stress, in&#xfb02;ammation, and insulin</span></p>
<p style="top:163.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">resistance [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">47</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">50</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. However, these treatments counteract the pathological e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of the fatty liver but</span></p>
<p style="top:176.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">do not target speci&#xfb01;c metabolic and signal transduction pathways.</span></p>
<p style="top:190.3pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Rather, a potential preventive role on NAFLD may be represented by INS. Indeed, the lack of</span></p>
<p style="top:203.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">INS and its compounds may worsen the fatty liver disease as shown in a zebra&#xfb01;sh model, in which a</span></p>
<p style="top:217.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">reduction of phosphatidylinositol synthesis increased endoplasmic reticulum stress and, consequently,</span></p>
<p style="top:230.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">hepatic steatosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">38</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. The role of INS in preventing the development of NAFLD is enhanced in rats,</span></p>
<p style="top:244.5pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">where the withdrawal of INS was associated with the onset of NAFLD, especially if accompanied with</span></p>
<p style="top:258.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">a diet rich in fat [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">51</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:271.4pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Rats with MI de&#xfb01;ciency had increased levels of triacylglycerols in the liver (2.6</span><span style="font-family:Pxsy,serif;font-size:10.0pt">&#x2212;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt"> and 5.3</span><span style="font-family:Pxsy,serif;font-size:10.0pt">&#x2212;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">fold</span></p>
<p style="top:285.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">higher for one and two weeks of treatment, respectively), a concomitant increase in the non-esteri&#xfb01;ed</span></p>
<p style="top:298.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">fatty acid levels in serum, and raised levels of cholesterol in the liver, causing fat accumulation,</span></p>
<p style="top:312.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">compared to controls [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">36</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">37</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. This condition may be reversible administrating MI and omega-3 fatty</span></p>
<p style="top:325.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">acids. In addition, MIs may reduce serum lipid levels lowering the risk of fatty liver [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">52</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:339.1pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Another fundamental role of INS in the prevention of fatty liver disease is to reduce the risk factors</span></p>
<p style="top:352.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">that cause steatosis. Indeed, MI and DCI are involved in the treatment of insulin resistance states.</span></p>
<p style="top:366.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Indeed, both isomers have been shown to exert insulin-mimetic action and to lower postprandial</span></p>
<p style="top:379.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">glucose [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">53</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Of note, DCI may improve the insulin sensitivity of</span><span style="font-family:EURM10,serif;font-size:10.0pt"> &#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">-cells, which could control glucagon</span></p>
<p style="top:393.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">levels in patients with diabetes mellitus.</span></p>
<p style="top:406.5pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Furthermore, patients with uncontrolled diabetes mellitus had also polyuria increasing the</span></p>
<p style="top:420.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">excretion of INS by kidneys and worsening the insulin resistance of patients.</span></p>
<p style="top:433.6pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">This evidence regarding INS de&#xfb01;ciency and NAFLD, diabetes, and dyslipidemia lead us to study</span></p>
<p style="top:447.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of supplementation of these molecules on chronic diseases.</span></p>
<p style="top:470.3pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">7. Inositol Supplementation in NAFLD</span></b></p>
<p style="top:489.7pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Compared to relatively vast preclinical and clinical research on other diseases, such as GDM,</span></p>
<p style="top:503.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">PCOS, and diabetes, only limited and introductory evidence is available on INS supplementation in</span></p>
<p style="top:516.8pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">NAFLD. Nevertheless, potentially relevant e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of INS in reducing liver fatty acids accumulation</span></p>
<p style="top:530.3pt;left:76.1pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">were enlightened by some preclinical studies in diet-induced nonalcoholic fatty liver animal models.</span></p>
<p style="top:543.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Lipids accumulation and NAFLD, as shown in genetic and animal models [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">54</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">], could activate unfolded</span></p>
<p style="top:557.3pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">protein response (UPR). This is a mechanism to avoid the accumulation of unfolding of proteins in</span></p>
<p style="top:570.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">the endoplasmic reticulum (ER) through the triggering of three distinct signal transduction pathways</span></p>
<p style="top:584.3pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">mediated by inositol requiring (IRE) 1</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">, PKR-like ER kinase (PERK), and activating transcription</span></p>
<p style="top:597.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">factor (ATF) 6</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">. These mechanisms are activated during ER stress and they promote insulin resistance</span></p>
<p style="top:611.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">and obesity in animal models. UPR also acts on numerous in&#xfb02;ammatory pathways, including NFkB,</span></p>
<p style="top:624.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">increasing liver damage and apoptosis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">55</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">56</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:638.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Studies on supplementation in animal models so far encompass MI, phytic acid, a six-polyphosphate</span></p>
<p style="top:651.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">form of INS, and Pinitol, a monomethylated form of DCI.</span></p>
<p style="top:665.5pt;left:97.7pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">The supplementation of all these INS forms reduced liver TG, CE, and free fatty acid content</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">&#x2013;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">.</span></p>
<p style="top:678.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Hepatic content of phospholipids was lowered by Pinitol, too [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Similarly, hamsters fed with a</span></p>
<p style="top:692.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">high-calorie, high-CE diet showed a reduced accumulation of white adipose tissue when supplemented</span></p>
<p style="top:705.9pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">with Pinitol. Pinitol reduced hepatic TG and CE, reduced plasmatic total CE and LDL, and increased</span></p>
<p style="top:719.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">HDL [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:733.0pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Hepatic activity of fatty acid synthesis enzymes was reduced by MI, phytic acid, and Pinitol</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt"> [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">39</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">.</span></p>
<p style="top:746.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Myoinositol reduced the expression of genes encoding enzymes for fatty acid synthesis [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:760.1pt;left:76.1pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Also, MI reduced the fructose-induced, carbohydrate-responsive element-binding protein, an important</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:495.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">9 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">lipogenesis transcription factor, binding to genes involved in fatty acid synthesis, though not reaching</span></p>
<p style="top:103.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">statistical signi&#xfb01;cance [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:117.0pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">Pinitol supplementation lessened the decline in hepatic levels of vitamin E, vitamin C, and reduced</span></p>
<p style="top:130.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">glutathione and reverted the reduction in the activity of enzymatic antioxidants like catalase, superoxide</span></p>
<p style="top:143.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">dismutase, glutathione peroxidase, and glutathione-S-transferase [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:157.5pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">These experiments were conducted in di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent animal models including rats fed with high-glucose,</span></p>
<p style="top:170.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">high-fructose or high fructose with supplementation with MI diets [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">45</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]; rats fed with high-sucrose</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">compared to corn starch diets [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">40</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]; streptozotocin-induced diabetic rats [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">41</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">] where Pinitol</span></p>
<p style="top:197.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">also exerted an anti-hyperglycemic e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect. Pinitol also reduced serum TNF-</span><span style="font-family:EURM10,serif;font-size:10.0pt">&#x3b1;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">, ALT, and AST in</span></p>
<p style="top:211.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">D-galactosamine-induced hepatic toxicity in high-fat fed rats [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">42</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:224.9pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Liver histopathology showed a diminished lipid accumulation in pinitol-treated hamsters,</span></p>
<p style="top:238.4pt;left:76.1pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">whereas the untreated group developed a fatty liver with signi&#xfb01;cantly larger adipocytes [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">43</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:252.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Likewise, pinitol normalized liver ultrastructure changes caused by streptozotocin-induced diabetes</span></p>
<p style="top:265.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">in rats, which caused periportal &#xfb01;brosis, hepatocyte and blood vessels distortion, microvesicular</span></p>
<p style="top:279.0pt;left:76.3pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">vacuolization, lipid accumulation, and mitochondria and glycogen reduction compared to untreated</span></p>
<p style="top:292.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">controls [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">44</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:306.0pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">These observations, albeit mainly in diabetes animal models, suggest the possibility to explore</span></p>
<p style="top:319.5pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the role of INS in clinical studies involving NAFLD patients, especially considering that NASH is an</span></p>
<p style="top:333.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">important cause of disease progression in the NAFLD spectrum [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">57</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:346.5pt;left:97.8pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Recently, a double-blind, placebo-controlled, randomized clinical trial (RCT) was performed to</span></p>
<p style="top:360.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">evaluate the e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ects of two di</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">erent doses of pinitol in 90 patients with NAFLD who were not taking</span></p>
<p style="top:373.5pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">medications and dietary supplements. After 12 weeks of treatment, no signi&#xfb01;cant between-group</span></p>
<p style="top:387.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erences in liver fat reduction were observed. However, there was a signi&#xfb01;cant reduction in liver fat</span></p>
<p style="top:400.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in the low dose pinitol, possibly due to the signi&#xfb01;cantly lower baseline liver fat content in the high-dose</span></p>
<p style="top:414.0pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">group. Pinitol treatment reduced AST levels compared to placebo. The ALT and GGT levels were</span></p>
<p style="top:427.6pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">non-di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erent between groups. Non-signi&#xfb01;cant di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erences were observed in the lipid pro&#xfb01;le between</span></p>
<p style="top:441.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">groups, unless a small nonsigni&#xfb01;cant reduction in total CE and LDL was observed. These &#xfb01;ndings were</span></p>
<p style="top:454.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">accompanied by the increased of urinary malondialdehyde (a marker of lipid oxidation) in the placebo</span></p>
<p style="top:468.2pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">group compared to pinitol arms. The levels of glutathione peroxidase (an enzyme involved in oxidative</span></p>
<p style="top:481.7pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">damage reduction) increased in both pinitol arms and decreased in placebo. The authors reported no</span></p>
<p style="top:495.1pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">signi&#xfb01;cant adverse events. In the same RCT, after a high-fat formula administration, pinitol reduced</span></p>
<p style="top:508.7pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">postprandial TG blood levels compared to the placebo [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">46</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. These observations, despite being limited</span></p>
<p style="top:522.2pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">by a small sample size and a relatively short observation period, are encouraging to further evaluate</span></p>
<p style="top:535.7pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">INS supplementation e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">cacy and safety in NAFLD in larger RCTs.</span></p>
<p style="top:558.9pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">8. Discussion</span></b></p>
<p style="top:578.4pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">We here report the &#xfb01;rst literature review on the role of INS in NAFLD, evaluating preclinical and</span></p>
<p style="top:592.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">clinical evidences. Despite the shortage of quality of evidence and the need for additional clinical trials,</span></p>
<p style="top:605.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">the bene&#xfb01;cial role of INS supplementation in NAFLD may be presumed.</span></p>
<p style="top:619.0pt;left:97.8pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">One of the mechanisms proposed for the underlying positive e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ects of INS supplements is based</span></p>
<p style="top:632.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">on the hypothesis that the increased availability of INS could intensify the insulin pathway through an</span></p>
<p style="top:645.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">enhanced signaling mediated by IPGs [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">14</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">,</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">58</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. Furthermore, INS could have a protective role against</span></p>
<p style="top:659.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">oxidative stress generated by cell metabolism [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">59</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Also, a positive e</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">ect on cytoskeleton regulation in</span></p>
<p style="top:672.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cystic ovaries interacting with steroidogenesis has been observed [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">59</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">]. Therefore, multiple theories</span></p>
<p style="top:686.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">explaining INS action in metabolic diseases have been proposed. However, as stated by Robert H.</span></p>
<p style="top:700.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">Mitchell, independently from the speci&#xfb01;c e</span><span style="font-family:Rpxr,serif;font-size:10.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">ect of INS, it appears clear that supplementation ensures</span></p>
<p style="top:713.4pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">a large availability of INS to supply central cell processes that rely on abundant INS-containing cell</span></p>
<p style="top:727.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">components [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">60</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">].</span></p>
<p style="top:740.4pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Despite no speci&#xfb01;c study regarding the role of INS in NAFLD-associated HCC existing,</span></p>
<p style="top:753.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">some interesting evidence on INS and HCC has been published. A tissue chromatography-mass</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">10 of 13</span></p>
<p style="top:89.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">spectrometry (GCMS) metabolomic analysis has shown a downregulation in INS levels in HCC liver</span></p>
<p style="top:103.3pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">tissues compared with non-HCC livers [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">61</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt">]. This is the result of a tumor-induced enhanced aerobic</span></p>
<p style="top:116.9pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">glycolysis due to the metabolic remodeling resulting from the perturbation in the PI3K&#x2013;AKT&#x2013;mTOR</span></p>
<p style="top:130.3pt;left:76.2pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">pathway.</span></p>
<p style="top:130.3pt;left:126.4pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Furthermore, another study on hepatocyte-speci&#xfb01;cTrim24-null mutant mouse model</span></p>
<p style="top:144.0pt;left:76.2pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">(spontaneously developing HCC), has explored the role myo-inositoltrispyrophosphate as an anticancer</span></p>
<p style="top:157.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">drug. The group of animals implemented with myo-inositoltrispyrophosphate showed no di</span><span style="font-family:Rpxr,serif;font-size:9.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">erences</span></p>
<p style="top:171.0pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">in terms of tumor growth except a two month improvement in overall survival [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">62</span><span style="font-family:URWPalladioL,serif;font-size:9.9pt">]. Numerous studies</span></p>
<p style="top:184.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">have reported the potential of inositols as anti-tumor compounds [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">63</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">], and this could be con&#xfb01;rmed</span></p>
<p style="top:198.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">also in NAFLD-associated HCC, but further studies are needed.</span></p>
<p style="top:211.4pt;left:97.8pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Despite many clinical trials evaluating the e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy of INS in di</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">erent settings, poor quality</span></p>
<p style="top:224.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">evidence is available on the safety of INS. A meta-analysis evaluating the safety and e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">cacy of</span></p>
<p style="top:238.5pt;left:76.5pt;line-height:9.9pt"><span style="font-family:URWPalladioL,serif;font-size:9.9pt">inositol supplementation in preterm infants for the prevention of the prematurity retinopathy showed</span></p>
<p style="top:251.9pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">no e</span><span style="font-family:Rpxr,serif;font-size:10.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">ect on the study outcomes but an increase in mortality in babies younger than 32 weeks [</span><span style="font-family:URWPalladioL,serif;font-size:10.0pt;color:#0774b7">64</span><span style="font-family:URWPalladioL,serif;font-size:10.1pt">].</span></p>
<p style="top:265.4pt;left:76.5pt;line-height:10.1pt"><span style="font-family:URWPalladioL,serif;font-size:10.1pt">Furthermore, studies evaluating safety reported short-term outcomes; thus, long-term follow-up</span></p>
<p style="top:279.0pt;left:76.5pt;line-height:10.0pt"><span style="font-family:URWPalladioL,serif;font-size:10.0pt">studies should be considered to obtain a better safety evaluation.</span></p>
<p style="top:301.9pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Supplementary Materials:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> The following are available online at</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7"> http:</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">www.mdpi.com</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">2072-6643</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">12</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">11</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">3379</span><span style="font-family:Rpxr,serif;font-size:9.0pt;color:#0774b7">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">s1</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">.</span></p>
<p style="top:312.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Suppl.1 Search strategy.</span></p>
<p style="top:328.1pt;left:76.2pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Author Contributions:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> A.P. and R.G. equally contributed to the paper&#x2019;s conceptualization, literature screening,</span></p>
<p style="top:338.2pt;left:76.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">and original draft preparation. D.M., A.R., R.R. and F.D.S. contributed to the literature screening and original</span></p>
<p style="top:348.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">draft preparation. V.A.F. contributed to the search strategy construction. F.A., E.I., B.P. contributed to the draft&#x2019;s</span></p>
<p style="top:358.6pt;left:76.5pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">review and editing. F.S. provided supervision and the &#xfb01;nal review of the paper. All authors have read and agreed</span></p>
<p style="top:368.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">to the published version of the manuscript.</span></p>
<p style="top:384.8pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Funding:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> This research received no external funding.</span></p>
<p style="top:400.9pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Con&#xfb02;icts of Interest:</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Riccardo Giossi reports support from Mylan for congress participation, outside of this paper.</span></p>
<p style="top:411.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Basilio Pintaudi declares to have received speaking fees from Novonordisk Spa, lo.li.pharma, Eli Lilly Italy Spa.</span></p>
<p style="top:421.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">He has participated on the Novo Nordisk Italy advisory boards. Francesco Scaglione declares to have received</span></p>
<p style="top:431.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">speaking fees from GSK, P&#xfb01;zer, and MSD in the past three years. All other authors declare no con&#xfb02;ict of interest.</span></p>
<p style="top:456.8pt;left:76.5pt;line-height:10.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:10.0pt">References</span></b></p>
<p style="top:476.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">1.</span></p>
<p style="top:476.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Younossi, Z.; Anstee, Q.M.; Marietti, M.; Hardy, T.; Henry, L.; Eslam, M.; George, J.; Bugianesi, E. Global</span></p>
<p style="top:489.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">burden of NAFLD and NASH: Trends, predictions, risk factors and prevention.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nat. Rev. Gastroenterol. Hepatol.</span></i></p>
<p style="top:502.3pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 11&#x2013;20. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:515.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2.</span></p>
<p style="top:515.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Charlton, M.R.; Burns, J.M.; Pedersen, R.A.; Watt, K.D.; Heimbach, J.K.; Dierkhising, R.A. Frequency and</span></p>
<p style="top:528.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Gastroenterology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:541.0pt;left:97.6pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">141</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1249&#x2013;1253. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:553.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">3.</span></p>
<p style="top:554.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Baratta, F.; Pastori, D.; Angelico, F.; Balla, A.; Paganini, A.M.; Cocomello, N.; Ferro, D.; Violi, F.; Sanyal, A.J.;</span></p>
<p style="top:566.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Del Ben, M. Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular</span></p>
<p style="top:579.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Events in a Prospective Study.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Clin. Gastroenterol. Hepatol. O</span></i><span style="font-family:Rpxi,serif;font-size:9.0pt">&#xfb00;</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. Clin. Pract. J. Am. Gastroenterol. Assoc.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span></p>
<p style="top:592.7pt;left:97.6pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 2324&#x2013;2331.e4. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:605.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.</span></p>
<p style="top:605.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Anstee, Q.M.; Mantovani, A.; Tilg, H.; Targher, G. Risk of cardiomyopathy and cardiac arrhythmias in</span></p>
<p style="top:618.5pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">patients with nonalcoholic fatty liver disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nat. Rev. Gastroenterol. Hepatol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 425&#x2013;439. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:631.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">5.</span></p>
<p style="top:631.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Hydes, T.; Buchanan, R.; Kennedy, O.J.; Fraser, S.; Parkes, J.; Roderick, P. Systematic review of the impact of</span></p>
<p style="top:644.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">non-alcoholic fatty liver disease on mortality and adverse clinical outcomes for individuals with chronic</span></p>
<p style="top:657.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">kidney disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> BMJ Open</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, e040970. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:670.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">6.</span></p>
<p style="top:670.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Kumar, J.; Memon, R.S.; Shahid, I.; Rizwan, T.; Zaman, M.; Menezes, R.G.; Kumar, S.; Siddiqi, T.J.; Usman, M.S.</span></p>
<p style="top:683.0pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence</span></p>
<p style="top:696.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">map.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Dig. Liver Dis. O</span></i><span style="font-family:Rpxi,serif;font-size:9.0pt">&#xfb00;</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:708.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">7.</span></p>
<p style="top:708.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Friedman, S.L.; Neuschwander-Tetri, B.A.; Rinella, M.; Sanyal, A.J. Mechanisms of NAFLD development</span></p>
<p style="top:721.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and therapeutic strategies.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nat. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 908&#x2013;922. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:734.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">8.</span></p>
<p style="top:734.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Balla, T.;</span></p>
<p style="top:734.6pt;left:142.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Bondeva, T.;</span></p>
<p style="top:734.6pt;left:203.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">V</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe1;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">rnai, P. How accurately can we image inositol lipids in living cells?</span></p>
<p style="top:747.6pt;left:97.5pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Trends Pharmacol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2000</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 21</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 238&#x2013;241. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">11 of 13</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">9.</span></p>
<p style="top:90.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wilcox, R.A. Measurement of calcium &#xfb02;uxes in permeabilized cells using a</span><span style="font-family:URWPalladioL,serif;font-size:7.0pt"> </span><sup><span style="font-family:URWPalladioL,serif;font-size:7.0pt">45</span></sup><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Ca</span><sup><span style="font-family:URWPalladioL,serif;font-size:7.0pt">2</span></sup><sup><span style="font-family:Rpxr,serif;font-size:7.0pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:8.9pt">uptake and release assay.</span></p>
<p style="top:103.6pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Methods Mol. Biol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2005</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 312</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 205&#x2013;212.</span></p>
<p style="top:116.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">10.</span></p>
<p style="top:116.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Pani, A.; Gironi, I.; Di Vieste, G.; Mion, E.; Bertuzzi, F.; Pintaudi, B. From Prediabetes to Type 2 Diabetes Mellitus</span></p>
<p style="top:129.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">in Women with Polycystic Ovary Syndrome: Lifestyle and Pharmacological Management.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Endocrinol.</span></i></p>
<p style="top:142.3pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 6276187. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:155.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">11.</span></p>
<p style="top:155.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Thomas, R.M.; Nechamen, C.A.; Mazurkiewicz, J.E.; Ulloa-Aguirre, A.; Dias, J.A. The adapter protein</span></p>
<p style="top:168.2pt;left:97.7pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2</span><span style="font-family:Rpxr,serif;font-size:8.9pt">+</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">)</span></p>
<p style="top:181.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">mobilization.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Endocrinology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 152</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1691&#x2013;1701. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:194.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">12.</span></p>
<p style="top:194.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Pace, C.; Tumino, D.; Russo, M.; Le Moli, R.; Naselli, A.; Borz</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xec;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, G.; Malandrino, P.; Frasca, F. Role of selenium</span></p>
<p style="top:206.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and myo-inositol supplementation on autoimmune thyroiditis progression.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Endocr. J.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:219.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">13.</span></p>
<p style="top:219.8pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Chiu, T.T.Y.; Rogers, M.S.; Briton-Jones, C.; Haines, C. E</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">ects of myo-inositol on the in-vitro maturation and</span></p>
<p style="top:232.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">subsequent development of mouse oocytes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Hum. Reprod.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2003</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 18</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 408&#x2013;416. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:245.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">14.</span></p>
<p style="top:245.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Croze, M.L.; Soulage, C.O. Potential role and therapeutic interests of myo-inositol in metabolic diseases.</span></p>
<p style="top:258.5pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biochimie</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 95</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1811&#x2013;1827. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:271.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">15.</span></p>
<p style="top:271.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Caputo, M.; Bona, E.; Leone, I.; Sam</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe0;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, M.T.; Nuzzo, A.; Ferrero, A.; Aimaretti, G.; Marzullo, P.; Prodam, F.</span></p>
<p style="top:284.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Inositols and metabolic disorders: From farm to bedside.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> J. Tradit. Complement. Med.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 10</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 252&#x2013;259.</span></p>
<p style="top:297.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:310.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">16.</span></p>
<p style="top:310.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hipps, P.P.; Sehgal, R.K.; Holland, W.H.; Sherman, W.R. Identi&#xfb01;cation and partial characterization of</span></p>
<p style="top:323.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">inositol: NAD</span><span style="font-family:Rpxr,serif;font-size:9.0pt">+</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> epimerase and inosose: NAD(P)H reductase from the fat body of the American cockroach,</span></p>
<p style="top:336.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Periplaneta americana L.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochemistry</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1973</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 4507&#x2013;4512. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:348.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">17.</span></p>
<p style="top:349.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Streb, H.; Irvine, R.F.; Berridge, M.J.; Schulz, I. Release of Ca</span><sup><span style="font-family:URWPalladioL,serif;font-size:7.0pt">2</span></sup><sup><span style="font-family:Rpxr,serif;font-size:7.0pt">+</span></sup><sup><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> </span></sup><span style="font-family:URWPalladioL,serif;font-size:8.9pt">from a nonmitochondrial intracellular store in</span></p>
<p style="top:361.8pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">pancreatic acinar cells by inositol-1,4,5-trisphosphate.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Nature</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1983</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 306</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 67&#x2013;69. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:374.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">18.</span></p>
<p style="top:374.8pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Larner, J.; Craig, J.W. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Diabetes Care</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1996</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:387.6pt;left:97.6pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">19</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 76&#x2013;78. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:400.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">19.</span></p>
<p style="top:400.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Santamaria, A.; Giordano, D.; Corrado, F.; Pintaudi, B.; Interdonato, M.L.; Vieste, G.D.; Di Benedetto, A.;</span></p>
<p style="top:413.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">D&#x2019;Anna, R. One-year e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ects of myo-inositol supplementation in postmenopausal women with metabolic</span></p>
<p style="top:426.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">syndrome.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Climacteric</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 490&#x2013;495. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:439.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">20.</span></p>
<p style="top:439.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Pintaudi, B.; Di Vieste, G.; Bonomo, M. The E</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">ectiveness of Myo-Inositol and D-Chiro Inositol Treatment in</span></p>
<p style="top:452.2pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Type 2 Diabetes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Endocrinol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 9132052. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:465.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">21.</span></p>
<p style="top:465.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Maeba, R.; Hara, H.; Ishikawa, H.; Hayashi, S.; Yoshimura, N.; Kusano, J.; Takeoka, Y.; Yasuda, D.; Okazaki, T.;</span></p>
<p style="top:478.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Kinoshita, M.; et al. Myo-inositol treatment increases serum plasmalogens and decreases small dense LDL,</span></p>
<p style="top:490.9pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">particularly in hyperlipidemic subjects with metabolic syndrome.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Nutr. Sci. Vitaminol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2008</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 54</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 196&#x2013;202.</span></p>
<p style="top:503.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:516.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">22.</span></p>
<p style="top:516.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Nordio, M.; Proietti, E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of</span></p>
<p style="top:529.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Eur. Rev.</span></i></p>
<p style="top:542.6pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Med. Pharmacol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 575&#x2013;581.</span></p>
<p style="top:555.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">23.</span></p>
<p style="top:555.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Capasso, I.; Esposito, E.; Maurea, N.; Montella, M.; Crispo, A.; De Laurentiis, M.; D&#x2019;Aiuto, M.; Frasci, G.;</span></p>
<p style="top:568.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Botti, G.; Grimaldi, M.; et al. Combination of inositol and alpha lipoic acid in metabolic syndrome-a</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ected</span></p>
<p style="top:581.3pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">women: A randomized placebo-controlled trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Trials</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 273. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:594.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">24.</span></p>
<p style="top:594.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Fruzzetti, F.; Perini, D.; Russo, M.; Bucci, F.; Gadducci, A. Comparison of two insulin sensitizers, metformin</span></p>
<p style="top:607.1pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">and myo-inositol, in women with polycystic ovary syndrome (PCOS).</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Gynecol. Endocrinol. O</span></i><span style="font-family:Rpxi,serif;font-size:9.1pt">&#xfb00;</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">. J. Int. Soc.</span></i></p>
<p style="top:620.1pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Gynecol. Endocrinol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 33</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 39&#x2013;42. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:633.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">25.</span></p>
<p style="top:632.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Grases, F.; Simonet, B.M.; Vucenik, I.; Prieto, R.M.; Costa-Bauz</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe1;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, A.; March, J.G.; Shamsuddin, A.M.</span></p>
<p style="top:645.8pt;left:97.7pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Absorption and excretion of orally administered inositol hexaphosphate (IP(6) or phytate) in humans.</span></p>
<p style="top:658.8pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Biofactors</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2001</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 53&#x2013;61. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:671.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">26.</span></p>
<p style="top:671.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Carlomagno, G.; De Grazia, S.; Unfer, V.; Manna, F. Myo-inositol in a new pharmaceutical form: A step</span></p>
<p style="top:684.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">forward to a broader clinical use.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Expert Opin. Drug Deliv.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2012</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 9</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 267&#x2013;271. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:697.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">27.</span></p>
<p style="top:697.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Holub, B.J. 1982 Borden Award lecture. Nutritional, biochemical, and clinical aspects of inositol and</span></p>
<p style="top:710.4pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">phosphatidylinositol metabolism.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Can. J. Physiol. Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1984</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 62</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1&#x2013;8. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:723.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">28.</span></p>
<p style="top:723.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Papaleo, E.; Unfer, V.; Baillargeon, J.-P.; Fusi, F.; Occhi, F.; De Santis, L. Myo-inositol may improve oocyte</span></p>
<p style="top:736.3pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Fertil. Steril.</span></i></p>
<p style="top:749.2pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 91</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1750&#x2013;1754. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">12 of 13</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">29.</span></p>
<p style="top:90.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Barak, Y.; Levine, J.; Glasman, A.; Elizur, A.; Belmaker, R.H. Inositol treatment of Alzheimer&#x2019;s disease:</span></p>
<p style="top:103.5pt;left:97.7pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">A double blind, cross-over placebo controlled trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Prog. Neuropsychopharmacol. Biol. Psychiatry</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1996</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span></p>
<p style="top:116.5pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 729&#x2013;735. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:129.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">30.</span></p>
<p style="top:129.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Vitagliano, A.; Saccone, G.; Cosmi, E.; Visentin, S.; Dessole, F.; Ambrosini, G.; Berghella, V. Inositol for the</span></p>
<p style="top:142.3pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">prevention of gestational diabetes: A systematic review and meta-analysis of randomized controlled trials.</span></p>
<p style="top:155.2pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Arch. Gynecol. Obstet.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 299</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 55&#x2013;68. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:168.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">31.</span></p>
<p style="top:168.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Carlomagno, G.; Unfer, V. Inositol safety: Clinical evidences.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Eur. Rev. Med. Pharmacol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 15</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 931&#x2013;936.</span></p>
<p style="top:181.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">32.</span></p>
<p style="top:181.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">&#xd6;zturan, A.; Arslan, S.; Kocaadam, B.; Elibol, E.; </span><sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">&#x2d9;</span></sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Imamo&#x2d8;glu, </span><sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">&#x2d9;</span></sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">I.; Karada&#x2d8;g, M.G. E</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ect of inositol and its</span></p>
<p style="top:193.9pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">derivatives on diabetes: A systematic review.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Crit. Rev. Food Sci. Nutr.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 59</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 1124&#x2013;1136. [</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">]</span></p>
<p style="top:206.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:219.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">33.</span></p>
<p style="top:219.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Pintaudi, B.; Di Vieste, G.; Corrado, F.; Lucisano, G.; Giunta, L.; D&#x2019;Anna, R.; Di Benedetto, A. E</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ects of</span></p>
<p style="top:232.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">myo-inositol on glucose variability in women with gestational diabetes.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Eur. Rev. Med. Pharmacol. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span></p>
<p style="top:245.6pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 6567&#x2013;6572.</span></p>
<p style="top:258.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">34.</span></p>
<p style="top:258.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Fraticelli, F.; Celentano, C.; Zecca, I.A.; Di Vieste, G.; Pintaudi, B.; Liberati, M.; Franzago, M.; Di Nicola, M.;</span></p>
<p style="top:271.4pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Vitacolonna, E. E</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ect of inositol stereoisomers at di</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">erent dosages in gestational diabetes: An open-label,</span></p>
<p style="top:284.3pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">parallel, randomized controlled trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Acta Diabetol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 55</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 805&#x2013;812. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:297.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">35.</span></p>
<p style="top:297.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lagan</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe0;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, A.S.; Garzon, S.; Casarin, J.; Franchi, M.; Ghezzi, F. Inositol in Polycystic Ovary Syndrome: Restoring</span></p>
<p style="top:310.2pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Fertility through a Pathophysiology-Based Approach.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Trends Endocrinol. Metab.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 29</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 768&#x2013;780. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:323.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">36.</span></p>
<p style="top:323.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hayashi, E.; Maeda, T.; Tomita, T. The e</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ect of myo-inositol de&#xfb01;ciency on lipid metabolism in rats. I.</span></p>
<p style="top:336.0pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">The alteration of lipid metabolism in myo-inositol de&#xfb01;cient rats.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochim. Biophys. Acta</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1974</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 360</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 134&#x2013;145.</span></p>
<p style="top:348.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:361.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">37.</span></p>
<p style="top:361.7pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Hayashi, E.; Maeda, T.; Tomita, T. The e</span><span style="font-family:Rpxr,serif;font-size:9.1pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.1pt">ect of myo-inositol de&#xfb01;ciency on lipid metabolism in rats. II.</span></p>
<p style="top:374.7pt;left:97.8pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">The mechanism of triacylglycerol accumulation in the liver of myo-inositol-de&#xfb01;cient rats.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochim. Biophys.</span></i></p>
<p style="top:387.6pt;left:97.7pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Acta</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1974</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 360</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 146&#x2013;155. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:400.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">38.</span></p>
<p style="top:400.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Thakur, P.C.; Stuckenholz, C.; Rivera, M.R.; Davison, J.M.; Yao, J.K.; Amsterdam, A.; Sadler, K.C.; Bahary, N.</span></p>
<p style="top:413.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Lack of de novo phosphatidylinositol synthesis leads to endoplasmic reticulum stress and hepatic steatosis</span></p>
<p style="top:426.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">in cdipt-de&#xfb01;cient zebra&#xfb01;sh.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Hepatology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 54</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 452&#x2013;462. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:439.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">39.</span></p>
<p style="top:439.4pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Katayama, T. E</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">ect of dietary addition of myo-inositol on lipid metabolism in rats fed sucrose or corn starch.</span></p>
<p style="top:452.2pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Nutr. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1994</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 14</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 699&#x2013;706. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:465.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">40.</span></p>
<p style="top:465.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Katayama, T. E</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ects of dietary myo-inositol or phytic acid on hepatic concentrations of lipids and hepatic</span></p>
<p style="top:478.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">activities of lipogenic enzymes in rats fed on corn starch or sucrose.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nutr. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1997</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 17</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 721&#x2013;728. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:490.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">41.</span></p>
<p style="top:491.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Geethan, P.K.M.A.; Prince, P.S.M. Antihyperlipidemic e</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">ect of D-pinitol on streptozotocin-induced diabetic</span></p>
<p style="top:503.8pt;left:97.6pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Wistar rats.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Biochem. Mol. Toxicol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2008</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 22</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 220&#x2013;224. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:516.8pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">42.</span></p>
<p style="top:516.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Zhou, Y.; Park, C.-M.; Cho, C.-W.; Song, Y.-S. Protective E</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">ect of Pinitol against D-Galactosamine-Induced</span></p>
<p style="top:529.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Hepatotoxicity in Rats Fed on a High-Fat Diet.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biosci. Biotechnol. Biochem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2008</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 72</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 1657&#x2013;1666. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:542.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">43.</span></p>
<p style="top:542.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Choi, M.-S.; Lee, M.-K.; Jung, U.J.; Kim, H.-J.; Do, G.-M.; Park, Y.B.; Jeon, S.-M. Metabolic response of</span></p>
<p style="top:555.4pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">soy pinitol on lipid-lowering, antioxidant and hepatoprotective action in hamsters fed-high fat and high</span></p>
<p style="top:568.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cholesterol diet.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Mol. Nutr. Food Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 53</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 751&#x2013;759. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:581.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">44.</span></p>
<p style="top:581.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Sivakumar, S.; Palsamy, P.; Subramanian, S.P. Attenuation of oxidative stress and alteration of hepatic</span></p>
<p style="top:594.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">tissue ultrastructure by D-pinitol in streptozotocin-induced diabetic rats.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Free Radic. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2010</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 44</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 668&#x2013;678.</span></p>
<p style="top:607.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:620.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">45.</span></p>
<p style="top:620.1pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Shimada, M.; Ichigo, Y.; Shirouchi, B.; Takashima, S.; Inagaki, M.; Nakagawa, T.; Hayakawa, T. Treatment with</span></p>
<p style="top:633.0pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">myo-inositol attenuates binding of the carbohydrate-responsive element-binding protein to the ChREBP-</span><span style="font-family:EURM10,serif;font-size:9.0pt">&#x3b2;</span></p>
<p style="top:645.8pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">and FASN genes in rat nonalcoholic fatty liver induced by high-fructose diet.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Nutr. Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 64</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 49&#x2013;55.</span></p>
<p style="top:658.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:671.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">46.</span></p>
<p style="top:671.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Lee, E.; Lim, Y.; Kwon, S.W.; Kwon, O. Pinitol consumption improves liver health status by reducing</span></p>
<p style="top:684.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">oxidative stress and fatty acid accumulation in subjects with non-alcoholic fatty liver disease: A randomized,</span></p>
<p style="top:697.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">double-blind, placebo-controlled trial.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Nutr. Biochem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 68</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 33&#x2013;41. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:710.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">47.</span></p>
<p style="top:710.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Del Ben, M.; Polimeni, L.; Baratta, F.; Pastori, D.; Angelico, F. The role of nutraceuticals for the treatment of</span></p>
<p style="top:723.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">non-alcoholic fatty liver disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Br. J. Clin. Pharmacol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 83</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 88&#x2013;95. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:736.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">48.</span></p>
<p style="top:736.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Lombardi,</span></p>
<p style="top:736.2pt;left:148.7pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">R.;</span></p>
<p style="top:736.2pt;left:170.8pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Onali,</span></p>
<p style="top:736.2pt;left:203.9pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">S.;</span></p>
<p style="top:736.2pt;left:224.7pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Thorburn,</span></p>
<p style="top:736.2pt;left:274.4pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">D.;</span></p>
<p style="top:736.2pt;left:297.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Davidson,</span></p>
<p style="top:736.2pt;left:347.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">B.R.;</span></p>
<p style="top:736.2pt;left:377.5pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Gurusamy,</span></p>
<p style="top:736.2pt;left:430.3pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">K.S.;</span></p>
<p style="top:736.2pt;left:460.0pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Tsochatzis,</span></p>
<p style="top:749.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): An attempted network</span><sup><span style="font-family:URWPalladioL,serif;font-size:9.1pt">E.</span></sup></p>
<p style="top:762.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">meta-analysis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Cochrane Database Syst. Rev.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2017</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 3</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, CD011640.</span></p>


<p style="top:56.6pt;left:76.5pt;line-height:8.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">Nutrients</span></i><b><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 2020</span></b><span style="font-family:URWPalladioL,serif;font-size:8.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.0pt"> 12</span></i><span style="font-family:URWPalladioL,serif;font-size:8.0pt">, 3379</span></p>
<p style="top:56.6pt;left:491.8pt;line-height:8.0pt"><span style="font-family:URWPalladioL,serif;font-size:8.0pt">13 of 13</span></p>
<p style="top:90.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">49.</span></p>
<p style="top:90.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Pastori, D.; Polimeni, L.; Baratta, F.; Pani, A.; Del Ben, M.; Angelico, F. The e</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">cacy and safety of statins for</span></p>
<p style="top:103.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">the treatment of non-alcoholic fatty liver disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> Dig. Liver Dis. O</span></i><span style="font-family:Rpxi,serif;font-size:9.1pt">&#xfb00;</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">. J. Ital. Soc. Gastroenterol. Ital. Assoc.</span></i></p>
<p style="top:116.5pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Study Liver</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2015</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 47</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 4&#x2013;11. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:129.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">50.</span></p>
<p style="top:129.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Del Ben, M.; Polimeni, L.; Baratta, F.; Pastori, D.; Lo</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">redo, L.; Angelico, F. Modern approach to the clinical</span></p>
<p style="top:142.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">management of non-alcoholic fatty liver disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> World J. Gastroenterol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2014</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 20</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 8341&#x2013;8350.</span></p>
<p style="top:155.2pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">51.</span></p>
<p style="top:155.3pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Chu, S.W.; Geyer, R.P. myo-Inositol action on gerbil intestine. Association of phosphatidylinositol metabolism</span></p>
<p style="top:168.1pt;left:97.7pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">with lipid clearance.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Biochim. Biophys. Acta</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 1982</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 710</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 63&#x2013;70. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:181.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">52.</span></p>
<p style="top:181.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">McCrea, H.J.; De Camilli, P. Mutations in phosphoinositide metabolizing enzymes and human disease.</span></p>
<p style="top:194.0pt;left:97.8pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Physiology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2009</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 24</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 8&#x2013;16. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:206.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">53.</span></p>
<p style="top:206.9pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Muscogiuri, G.; Palomba, S.; Lagan</span><span style="font-family:VnURWPalladioL,serif;font-size:9.0pt">&#xe0;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, A.S.; Orio, F. Inositols in the Treatment of Insulin-Mediated Diseases.</span></p>
<p style="top:219.8pt;left:98.1pt;line-height:9.0pt"><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Int. J. Endocrinol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 3058393. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:232.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">54.</span></p>
<p style="top:232.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ozcan, U.; Cao, Q.; Yilmaz, E.; Lee, A.-H.; Iwakoshi, N.N.; Ozdelen, E.; Tuncman, G.; G&#xf6;rg&#xfc;n, C.;</span></p>
<p style="top:245.5pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Glimcher, L.H.; Hotamisligil, G.S. Endoplasmic reticulum stress links obesity, insulin action, and type 2</span></p>
<p style="top:258.5pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">diabetes.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Science</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2004</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 306</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 457&#x2013;461. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:271.4pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">55.</span></p>
<p style="top:271.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Wu, S.; Tan, M.; Hu, Y.; Wang, J.-L.; Scheuner, D.; Kaufman, R.J. Ultraviolet light activates NFkappaB through</span></p>
<p style="top:284.3pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">translational inhibition of IkappaBalpha synthesis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> J. Biol. Chem.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2004</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 279</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 34898&#x2013;34902. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:297.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">56.</span></p>
<p style="top:297.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Malhi, H.; Kaufman, R.J. Endoplasmic reticulum stress in liver disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> J. Hepatol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2011</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> 54</span></i><span style="font-family:URWPalladioL,serif;font-size:9.1pt">, 795&#x2013;809.</span></p>
<p style="top:310.2pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:323.1pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">57.</span></p>
<p style="top:323.2pt;left:98.0pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Sanyal, A.J. Past, present and future perspectives in nonalcoholic fatty liver disease.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Nat. Rev. Gastroenterol. Hepatol.</span></i></p>
<p style="top:336.0pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 16</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 377&#x2013;386. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:348.9pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">58.</span></p>
<p style="top:349.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Noventa, M.; Vitagliano, A.; Quaranta, M.; Borgato, S.; Abdulrahim, B.; Gizzo, S. Preventive and Therapeutic</span></p>
<p style="top:361.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Role of Dietary Inositol Supplementation in Periconceptional Period and During Pregnancy: A Summary of</span></p>
<p style="top:374.7pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Evidences and Future Applications.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Reprod. Sci.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 23</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 278&#x2013;288. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:387.6pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">59.</span></p>
<p style="top:387.7pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Bizzarri, M.; Cucina, A.; Dinicola, S.; Harrath, A.H.; Alwasel, S.H.; Unfer, V.; Bevilacqua, A. Does myo-inositol</span></p>
<p style="top:400.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">e</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb00;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">ect on PCOS follicles involve cytoskeleton regulation?</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> Med. Hypotheses</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 91</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 1&#x2013;5. [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">] [</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt;color:#0774b7">PubMed</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">]</span></p>
<p style="top:413.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">60.</span></p>
<p style="top:413.5pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Michell, R.H. Do inositol supplements enhance phosphatidylinositol supply and thus support endoplasmic</span></p>
<p style="top:426.4pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">reticulum function?</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Br. J. Nutr.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2018</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 120</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 301&#x2013;316. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:439.3pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">61.</span></p>
<p style="top:439.2pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Beyo&#x2d8;glu, D.; Imbeaud, S.; Maurhofer, O.; Bioulac-Sage, P.; Zucman-Rossi, J.; Dufour, J.-F.; Idle, J.R.</span></p>
<p style="top:452.2pt;left:97.8pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic</span></p>
<p style="top:465.1pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">classi&#xfb01;cation.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Hepatology</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2013</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 58</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 229&#x2013;238. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:478.0pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">62.</span></p>
<p style="top:478.0pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Ignat, M.; Akladios, C.Y.; Lindner, V.; Khetchoumian, K.; Teletin, M.; Muttter, D.; Aprahamian, P.M.;</span></p>
<p style="top:491.0pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Marescaux, J. Development of a methodology for</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> in vivo</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> follow-up of hepatocellular carcinoma in hepatocyte</span></p>
<p style="top:503.9pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">speci&#xfb01;c Trim24-null mice treated with myo-inositol trispyrophosphate.</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> J. Exp. Clin. Cancer Res.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:8.9pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:8.9pt"> 35</span></i><span style="font-family:URWPalladioL,serif;font-size:8.9pt">, 155.</span></p>
<p style="top:516.8pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">[</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:529.7pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">63.</span></p>
<p style="top:529.6pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">Bizzarri, M.; Dinicola, S.; Bevilacqua, A.; Cucina, A. Broad Spectrum Anticancer Activity of Myo-Inositol</span></p>
<p style="top:542.6pt;left:98.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">and Inositol Hexakisphosphate.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> Int. J. Endocrinol.</span></i><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2016</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 5616807. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:555.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">64.</span></p>
<p style="top:555.6pt;left:98.1pt;line-height:8.9pt"><span style="font-family:URWPalladioL,serif;font-size:8.9pt">Du, Y.; He, Y.; Wang, Y.-L.; Zhou, J.-G.; Chen, C. The e</span><span style="font-family:Rpxr,serif;font-size:8.9pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:8.9pt">cacy and safety of inositol supplementation in preterm</span></p>
<p style="top:568.3pt;left:98.1pt;line-height:9.1pt"><span style="font-family:URWPalladioL,serif;font-size:9.1pt">infants to prevent retinopathy of prematurity: A systematic review and meta-analysis.</span><i><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> BMC Ophthalmol.</span></i></p>
<p style="top:581.3pt;left:98.1pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">2019</span></b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">,</span><i><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 19</span></i><span style="font-family:URWPalladioL,serif;font-size:9.0pt">, 135. [</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt;color:#0774b7">CrossRef</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">]</span></p>
<p style="top:603.4pt;left:76.5pt;line-height:9.0pt"><b><span style="font-family:URWPalladioL,serif;font-size:9.0pt">Publisher&#x2019;s Note:</span></b><span style="font-family:URWPalladioL,serif;font-size:9.1pt"> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional</span></p>
<p style="top:613.5pt;left:76.5pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">a</span><span style="font-family:Rpxr,serif;font-size:9.0pt">&#xfb03;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">liations.</span></p>
<img style="position:absolute;transform:matrix(.221696,0,-0,.221696,-91.16266,777.5417)" src="data:image/png;base64,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">
<p style="top:633.1pt;left:167.8pt;line-height:9.0pt"><span style="font-family:Rpcxr,serif;font-size:9.0pt">&#xa9;</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt"> 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access</span></p>
<p style="top:646.0pt;left:169.4pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">article distributed under the terms and conditions of the Creative Commons Attribution</span></p>
<p style="top:658.9pt;left:169.1pt;line-height:9.0pt"><span style="font-family:URWPalladioL,serif;font-size:9.0pt">(CC BY) license (http:</span><span style="font-family:Rpxr,serif;font-size:9.0pt">//</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">creativecommons.org</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">licenses</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">by</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">4.0</span><span style="font-family:Rpxr,serif;font-size:9.0pt">/</span><span style="font-family:URWPalladioL,serif;font-size:9.0pt">).</span></p>

</div>
